Vlado Perkovic | Academic Influence

Vlado Perkovic's AcademicInfluence.com Rankings

Vlado Perkovic

Computer Science

#5201

World Rank

#5495

Historical Rank

Computational Linguistics

#668

World Rank

#680

Historical Rank

Machine Learning

#1290

World Rank

#1310

Historical Rank

Artificial Intelligence

#1520

World Rank

#1549

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Vlado Perkovic's Degrees

Bachelors Computer Science University of Zagreb
Masters Computer Science University of Zagreb

Similar Degrees You Can Earn

Why Is Vlado Perkovic Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Vlado Perkovic is an Australian renal physician and researcher who is the Provost at the University of New South Wales, Sydney, having previously been Dean of Medicine & Health at that University between 2019 and 2023.

(See a Problem?)

Vlado Perkovic's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes (2017) (3090)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. (2019) (2717)
Worldwide access to treatment for end-stage kidney disease: a systematic review (2015) (1375)
Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. (2009) (850)
Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis (2016) (826)
Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis (2010) (801)
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial (2019) (749)
Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials (2008) (686)
Kidney disease: Improving global outcomes (KDIGO) blood pressure work group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease (2012) (637)
Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. (2015) (627)
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy (2017) (580)
A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension (2016) (565)
Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. (2014) (503)
Coffee, decaffeinated coffee, and tea consumption in relation to incident type 2 diabetes mellitus: a systematic review with meta-analysis. (2009) (489)
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. (2019) (464)
Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data (2014) (449)
Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials (2008) (424)
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. (2018) (410)
Is low birth weight an antecedent of CKD in later life? A systematic review of observational studies. (2009) (388)
Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. (2016) (380)
Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials (2009) (380)
Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus (2018) (334)
The burden of blood pressure-related disease: a neglected priority for global health. (2007) (328)
Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial (2017) (317)
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events (2017) (308)
Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial. (2013) (307)
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial (2019) (306)
Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects. (2017) (290)
Meta-analysis: Erythropoiesis-Stimulating Agents in Patients With Chronic Kidney Disease (2010) (267)
Association of Positive Airway Pressure With Cardiovascular Events and Death in Adults With Sleep Apnea: A Systematic Review and Meta-analysis (2017) (267)
Guideline for the diagnosis and management of hypertension in adults — 2016 (2016) (265)
Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. (2013) (264)
Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction (2013) (264)
Lowering blood pressure reduces renal events in type 2 diabetes. (2009) (251)
Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis (2013) (246)
Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. (2008) (226)
Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency. (2019) (218)
The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. (2014) (217)
Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials. (2016) (212)
Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials (2013) (203)
The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials (2011) (203)
Omega 3 Fatty Acids and Cardiovascular Outcomes: Systematic Review and Meta-Analysis (2012) (202)
Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes (2014) (201)
The Relationship between Proteinuria and Coronary Risk: A Systematic Review and Meta-Analysis (2008) (199)
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups (2019) (191)
Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function (2018) (186)
Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON (2016) (185)
Effects of Allopurinol on the Progression of Chronic Kidney Disease. (2020) (183)
Long-term cancer risk of immunosuppressive regimens after kidney transplantation. (2010) (183)
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis (2021) (181)
The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics (2017) (180)
Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. (2014) (178)
Systematic Review: Sodium Bicarbonate Treatment Regimens for the Prevention of Contrast-Induced Nephropathy (2009) (177)
Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. (2013) (168)
Corticosteroid therapy in IgA nephropathy. (2012) (167)
Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. (2010) (166)
A Randomized Trial of Intensive versus Standard Blood-Pressure Control. (2016) (160)
Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF. (2016) (155)
Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta‐analysis (2019) (153)
Chronic kidney disease and the global NCDs agenda (2017) (146)
Effects of fibrates in kidney disease: a systematic review and meta-analysis. (2012) (141)
Redefining Blood-Pressure Targets--SPRINT Starts the Marathon. (2015) (139)
Effects of the Mediterranean Diet on Cardiovascular Outcomes—A Systematic Review and Meta-Analysis (2016) (138)
Proteinuria and stroke: a meta-analysis of cohort studies. (2009) (136)
Parathyroid Hormone Has a Prosclerotic Effect on Vascular Smooth Muscle Cells (2002) (135)
Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis. (2011) (133)
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. (2014) (128)
The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study (2015) (126)
Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA‐T2D trial (2017) (126)
Chronic kidney disease (2021) (125)
Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal (CANVAS‐R): A randomized, placebo‐controlled trial (2017) (122)
Antihypertensive agents for preventing diabetic kidney disease. (2012) (121)
Sodium‐Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis (2020) (120)
Isolated Low Levels of High-Density Lipoprotein Cholesterol Are Associated With an Increased Risk of Coronary Heart Disease: An Individual Participant Data Meta-Analysis of 23 Studies in the Asia-Pacific Region (2011) (119)
Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus. (2019) (113)
Effects of Antiplatelet Therapy on Mortality and Cardiovascular and Bleeding Outcomes in Persons With Chronic Kidney Disease (2012) (112)
The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis (2012) (109)
Status of care for end stage kidney disease in countries and regions worldwide: international cross sectional survey (2019) (109)
Management of patients with diabetes and CKD: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. (2016) (108)
Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes and Stage 3 Nephropathy (2014) (106)
Prediction of kidney-related outcomes in patients with type 2 diabetes. (2012) (106)
Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study. (2007) (104)
GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials. (2019) (103)
Cardiovascular disease in patients with chronic kidney disease (2014) (101)
Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS‐R trials (2017) (99)
High prevalence of chronic kidney disease in Thailand. (2008) (99)
Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials. (2011) (98)
Effects of Intensive Blood Pressure Lowering on Cardiovascular and Renal Outcomes: A Systematic Review and Meta-Analysis (2012) (98)
Effect of hemodiafiltration or hemofiltration compared with hemodialysis on mortality and cardiovascular disease in chronic kidney failure: a systematic review and meta-analysis of randomized trials. (2014) (97)
Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology (SONG) implementation workshop. (2018) (97)
Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease—Improving Global Outcomes (KDIGO) Controversies Conference (2017) (94)
Intensities of renal replacement therapy in acute kidney injury: a systematic review and meta-analysis. (2010) (88)
HMG CoA reductase inhibitors (statins) for dialysis patients. (2009) (87)
Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes. (2015) (87)
Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Chronic Kidney Disease According to Baseline HbA1c, Including Those with HbA1c <7%: Results From the CREDENCE Trial. (2019) (86)
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. (2020) (83)
Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program (2019) (83)
Effects of SGLT2 inhibitors on cardiovascular outcomes (2012) (83)
Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program. (2019) (81)
Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. (2010) (79)
HMG CoA reductase inhibitors (statins) for kidney transplant recipients. (2009) (79)
Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy. (2019) (78)
Survival of elderly dialysis patients is predicted by both patient and practice characteristics. (2012) (77)
Efficacy and safety of canagliflozin when used in conjunction with incretin‐mimetic therapy in patients with type 2 diabetes (2016) (77)
HMG CoA reductase inhibitors (statins) for dialysis patients. (2013) (77)
Preoperative Estimates of Glomerular Filtration Rate as Predictors of Outcome after Surgery: A Systematic Review and Meta-analysis (2013) (76)
Antiplatelet therapy to prevent hemodialysis vascular access failure: systematic review and meta-analysis. (2013) (76)
Comparative Effectiveness of 12 Treatment Strategies for Preventing Contrast-Induced Acute Kidney Injury: A Systematic Review and Bayesian Network Meta-analysis. (2017) (75)
Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes. (2020) (74)
Research Priorities in CKD: Report of a National Workshop Conducted in Australia. (2015) (73)
The impact of the COVID-19 pandemic on medical education. (2020) (72)
Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk (2018) (69)
Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. (2019) (68)
The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis. (2016) (68)
Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes - A systematic review. (2018) (66)
The Relative and Combined Ability of High-Sensitivity Cardiac Troponin T and N-Terminal Pro-B-Type Natriuretic Peptide to Predict Cardiovascular Events and Death in Patients With Type 2 Diabetes (2013) (66)
Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. (2015) (65)
Antioxidants for chronic kidney disease. (2012) (64)
SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation (2020) (63)
Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial (2010) (62)
Relationship Between Levels of Advanced Glycation End Products and Their Soluble Receptor and Adverse Outcomes in Adults With Type 2 Diabetes (2015) (61)
Accelerated progression of calcific aortic stenosis in dialysis patients. (2002) (61)
Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy (2018) (60)
Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial. (2020) (60)
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. (2020) (60)
Outcomes of extended-hours hemodialysis performed predominantly at home. (2013) (60)
Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis (2021) (60)
A Trial of Extending Hemodialysis Hours and Quality of Life. (2017) (59)
Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial. (2020) (59)
Resting Heart Rate and the Risk of Microvascular Complications in Patients With Type 2 Diabetes Mellitus (2012) (58)
Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease (2019) (58)
HMG CoA reductase inhibitors (statins) for kidney transplant recipients. (2014) (57)
Blood Pressure Is a Major Risk Factor for Renal Death: An Analysis of 560 352 Participants From the Asia-Pacific Region (2009) (57)
Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. (2021) (56)
Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. (2019) (56)
Renal effects of canagliflozin in type 2 diabetes mellitus (2015) (55)
Cardiovascular risk management in chronic kidney disease in general practice (the AusHEART study). (2012) (54)
Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program (2019) (51)
SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. (2020) (50)
Circulating bone morphogenetic protein-7 and transforming growth factor-β1 are better predictors of renal end points in patients with type 2 diabetes mellitus. (2013) (50)
Sharing Data from Cardiovascular Clinical Trials--A Proposal. (2016) (50)
Challenges of conducting a trial of uric-acid-lowering therapy in CKD (2011) (49)
Accelerated Progression of Calcific Aortic Stenosis in Dialysis Patients (2003) (49)
Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes. (2020) (49)
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. (2021) (48)
Socioeconomic disadvantage and kidney disease in the United States, Australia, and Thailand. (2008) (48)
Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial. (2020) (48)
Phosphate in early chronic kidney disease: Associations with clinical outcomes and a target to reduce cardiovascular risk (2012) (46)
Cyclosporine Withdrawal Improves Long-Term Graft Survival in Renal Transplantation (2009) (45)
Representativeness of Randomized Clinical Trial Cohorts in End-stage Kidney Disease: A Meta-analysis. (2019) (43)
Canagliflozin and Stroke in Type 2 Diabetes Mellitus (2018) (43)
Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis. (2021) (42)
Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index: a meta-analysis of randomised trials (2015) (42)
Tripterygium preparations for the treatment of CKD: a systematic review and meta-analysis. (2013) (42)
The Validity of Left Ventricular Mass as a Surrogate End Point for All-Cause and Cardiovascular Mortality Outcomes in People With CKD: A Systematic Review and Meta-analysis. (2016) (42)
Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis. (2015) (41)
Changes in Albuminuria and the Risk of Major Clinical Outcomes in Diabetes: Results From ADVANCE-ON (2017) (41)
Warfarin Initiation, Atrial Fibrillation, and Kidney Function: Comparative Effectiveness and Safety of Warfarin in Older Adults With Newly Diagnosed Atrial Fibrillation. (2017) (41)
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials (2022) (40)
Lower blood pressure and risk of recurrent stroke in patients with chronic kidney disease: PROGRESS trial. (2008) (40)
Effects of salt substitute on pulse wave analysis among individuals at high cardiovascular risk in rural China: a randomized controlled trial (2009) (40)
Effects of ischaemic conditioning on major clinical outcomes in people undergoing invasive procedures: systematic review and meta-analysis (2016) (40)
Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease (2021) (39)
Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial (2015) (38)
Acute Increases in Serum Creatinine After Starting Angiotensin-Converting Enzyme Inhibitor-Based Therapy and Effects of its Continuation on Major Clinical Outcomes in Type 2 Diabetes Mellitus: The ADVANCE Trial (2019) (37)
A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD). (2020) (37)
Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA–T2D™ trial (2015) (36)
Treatment of Renovascular Disease with Percutaneous Stent Insertion: Long-Term Outcomes (2001) (36)
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients. (2017) (36)
HMG CoA reductase inhibitors (statins) for dialysis patients. (2009) (36)
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials (2022) (35)
Associations between body mass index and the risk of renal events in patients with type 2 diabetes (2018) (34)
International consensus definitions of clinical trial outcomes for kidney failure: 2020. (2020) (34)
Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point? (2017) (34)
The β-Blocker to Lower Cardiovascular Dialysis Events (BLOCADE) Feasibility Study: A Randomized Controlled Trial. (2016) (34)
Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers (2016) (33)
Is Doubling of Serum Creatinine a Valid Clinical ‘Hard’ Endpoint in Clinical Nephrology Trials? (2011) (33)
Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial (2020) (32)
Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial. (2022) (32)
Are SGLT2 Inhibitors Ready for Prime Time for CKD? (2017) (32)
Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease (2021) (32)
Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy. (2015) (32)
Trials in kidney disease--time to EVOLVE. (2012) (31)
Pharmacological intervention in renal fibrosis and vascular sclerosis. (2001) (30)
The risk of cancer in people with diabetes and chronic kidney disease. (2012) (30)
The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study (2019) (30)
Prospective evaluation of aortic stenosis in end-stage kidney disease: a more fulminant process? (2011) (29)
Anticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end-stage kidney disease. (2016) (29)
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. (2009) (28)
Sodium‐glucose co‐transporter‐2 inhibitors with and without metformin: A meta‐analysis of cardiovascular, kidney and mortality outcomes (2020) (28)
Blood Pressure Lowering in Type 2 Diabetes A Systematic Review andMeta-analysis (2015) (28)
A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial. (2015) (27)
Anticoagulant therapies for the prevention of intravascular catheters malfunction in patients undergoing haemodialysis: systematic review and meta-analysis of randomized, controlled trials. (2013) (27)
Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program. (2020) (27)
Interventions for erythropoietin-resistant anaemia in dialysis patients. (2013) (27)
Prevalence of chronic kidney disease in Asia: a systematic review and analysis (2022) (27)
The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program (2019) (27)
The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program (2019) (27)
Comparative effectiveness and tolerance of immunosuppressive treatments for idiopathic membranous nephropathy: A network meta-analysis (2017) (27)
Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial (2021) (27)
Renal and cardio-protective effects of direct renin inhibition: a systematic literature review (2009) (27)
Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER (2021) (26)
Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories: Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Multinational Trial. (2020) (26)
Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study (2019) (26)
Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial. (2018) (26)
Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis (2021) (25)
Relationship between Serum Uric Acid Levels and Chronic Kidney Disease in a Japanese Cohort with Normal or Mildly Reduced Kidney Function (2015) (25)
Combination of Changes in Estimated GFR and Albuminuria and the Risk of Major Clinical Outcomes. (2019) (25)
Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis. (2021) (24)
Co-payments for health care: what is their real cost? (2015) (24)
Efficacy and safety of Canagliflozin (CANA), an inhibitor of Sodium Glucose Co-Transporter 2 (SGLT2), added on to insulin therapy with or without oral agents in type 2 diabetes (T2D) (2013) (23)
Managing cardiovascular risk in people with chronic kidney disease: a review of the evidence from randomized controlled trials (2011) (23)
ADVANCE: breaking new ground in type 2 diabetes (2006) (22)
Lowering cholesterol in chronic kidney disease: is it safe and effective? (2015) (21)
EFFECTS OF THE MEDITERRANEAN DIET ON CARDIOVASCULAR OUTCOMES: A SYSTEMATIC REVIEW AND META-ANALYSIS (2015) (21)
The cost-effectiveness of early detection and intervention to prevent the progression of chronic kidney disease in Australia (2006) (21)
Effects of Canagliflozin on Cardiovascular, Renal, and Safety Outcomes in Participants With Type 2 Diabetes and Chronic Kidney Disease According to History of Heart Failure: Results From the CREDENCE Trial. (2020) (20)
Establishing a clinical trials network in nephrology: experience of the Australasian Kidney Trials Network (2013) (20)
Intensive glycemic control and renal outcome. (2011) (19)
Design and participant baseline characteristics of ‘A Clinical Trial of IntensiVE Dialysis’: The ACTIVE Dialysis Study (2015) (19)
Action plan for optimizing the design of clinical trials in chronic kidney disease. (2017) (19)
Global randomized trials: the promise of India and China. (2012) (19)
Interventions for lowering plasma homocysteine levels in kidney transplant recipients. (2015) (18)
Baseline characteristics and enrichment results of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial. (2018) (18)
Reanalysis of the Crystalloid versus Hydroxyethyl Starch Trial (CHEST). (2017) (17)
Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future? (2020) (17)
Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial (2019) (17)
The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial (2020) (17)
Canagliflozin Reduces Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial. (2021) (17)
mTOR inhibition in autosomal-dominant polycystic kidney disease (ADPKD): the question remains open. (2013) (17)
New clinical trial designs for establishing drug efficacy and safety in a precision medicine era (2018) (16)
The CARI guidelines. Dialysis adequacy (HD) guidelines. (2005) (16)
Baseline characteristics and enrichment results from the SONAR trial (2018) (16)
Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering (2019) (15)
Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program (2020) (15)
Current status of health systems financing and oversight for end-stage kidney disease care: a cross-sectional global survey (2021) (15)
The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy (2017) (15)
Isolated Low Levels of High-Density Lipoprotein Cholesterol Are Associated With an Increased Risk of Coronary Heart DiseaseClinical Perspective (2011) (15)
The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program. (2020) (15)
Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME® trial. (2020) (15)
Effect of methylprednisolone on acute kidney injury in patients undergoing cardiac surgery with a cardiopulmonary bypass pump: a randomized controlled trial (2019) (15)
Hemodialysis Use and Practice Patterns: An International Survey Study. (2020) (14)
Closing the gap between evidence and practice in chronic kidney disease. (2017) (13)
Industry-sponsored clinical trials in emerging markets: time to review the terms of engagement. (2013) (13)
Diuretics: A modern day treatment option? (Review Article) (2006) (13)
Quality of life in caregivers compared with dialysis recipients: The Co‐ACTIVE sub‐study of the ACTIVE dialysis trial (2019) (12)
Renal trials in diabetes need a platform: time for a global approach? (2017) (12)
Dietary Sodium Reduction Reduces Albuminuria: A Cluster Randomized Trial. (2019) (12)
Association between serum hepcidin‐25 and primary resistance to erythropoiesis‐stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial (2017) (12)
Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis (2021) (12)
Interventions for lowering plasma homocysteine levels in dialysis patients. (2016) (11)
The effects of dipeptidyl peptidase‐4 inhibitors on kidney outcomes (2020) (11)
Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program (2019) (11)
Diuretics: a modern day treatment option? (2006) (11)
Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program. (2020) (11)
Global capacity for clinical research in nephrology: a survey by the International Society of Nephrology. (2018) (11)
Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program (2021) (11)
Clinical characteristics of IgA nephropathy associated with low complement 4 levels (2015) (11)
Varying Association of Extended Hours Dialysis with Quality of Life. (2019) (10)
Hematuria in thin basement membrane nephropathy. (2005) (10)
Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS Program and CREDENCE trial. (2021) (10)
A challenge to chronic kidney disease in Asia: The report of the second Asian Forum of Chronic Kidney Disease Initiative (2010) (10)
Sirolimus: a single center experience in combination with calcineurin inhibitors. (2003) (9)
Association between serum alkaline phosphatase and primary resistance to erythropoiesis stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial (2015) (9)
Trial Design Innovations to Accelerate Therapeutic Advances in Chronic Kidney Disease: Moving from Single Trials to an Ongoing Platform. (2018) (9)
Association between TNF Receptors and KIM-1 with Kidney Outcomes in Early-Stage Diabetic Kidney Disease (2021) (9)
POS-546 EFFICACY AND SAFETY OF IPTACOPAN IN IgA NEPHROPATHY: RESULTS OF A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 2 STUDY AT 6 MONTHS (2022) (9)
Mortality in dialysis patients may not be associated with ESA dose: a 2-year prospective observational study (2012) (8)
Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin with renin–angiotensin system inhibitors in type 2 diabetic patients with albuminuria (2018) (8)
Predictors of change in left-ventricular structure and function in a trial of extended hours hemodialysis. (2020) (8)
Association Between Circulating GDF‐15 and Cardio‐Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial (2021) (8)
The Affordable Dialysis Prize steams ahead (2016) (8)
Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients (2022) (8)
The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics (2021) (8)
CANAGLIFLOZIN (CANA) REDUCES CARDIOVASCULAR (CV) AND RENAL EVENTS INDEPENDENT OF BASELINE HEART FAILURE (HF): A CREDENCE SECONDARY ANALYSIS (2020) (7)
Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis (2022) (7)
Prevalence and risk factors of prediabetes after renal transplantation : a single-centre cohort study in 200 consecutive patients (7)
Chronic kidney disease in Asia: Protocol for a collaborative overview (2017) (7)
The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial (2016) (7)
ADVANCE: lessons from the run-in phase of a large study in type 2 diabetes. (2006) (7)
Availability, coverage, and scope of health information systems for kidney care across world countries and regions. (2020) (7)
Kidney Disease in Diabetes (2014) (7)
Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy. (2022) (7)
Dose of haemodialysis (2005) (7)
Dialysis Adequacy (HD) Guidelines (2005) (7)
Abstract #259 Cardiovascular and Renal Outcomes with Canagliflozin in People with Type 2 Diabetes According to Baseline use of Metformin (2019) (6)
New insights from ADVANCE (2007) (6)
An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials. (2020) (6)
Effect of extended hours dialysis on markers of chronic kidney disease-mineral and bone disorder in the ACTIVE Dialysis study (2019) (6)
ACEIs for cardiovascular risk reduction--have we taken our eye off the ball? (2013) (6)
The impact of the COVID‐19 pandemic on medical education (2020) (6)
Effect of extended hours dialysis on sleep quality in a randomized trial (2019) (6)
Eff ects of fi brates on cardiovascular outcomes: a systematic review and meta-analysis (2010) (6)
Kidney Disease in Diabetes [chapter 3] (2014) (6)
The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial (2020) (6)
Inter‐individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial (2020) (6)
Efficacy and Safety of Canaglif lozin, an Inhibitor of Sodium Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes (2014) (6)
The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function (2021) (6)
Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial (2021) (6)
Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients A Randomized Clinical Trial (2022) (6)
The rationale and design of the Beta‐blocker to LOwer CArdiovascular Dialysis Events (BLOCADE) Feasibility Study (2015) (6)
Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial (2017) (6)
Sodium‐glucose co‐transporter‐2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and meta‐analysis (2020) (6)
International trials in middle-income countries: different local scenarios require different ethical approaches (2016) (5)
No evidence of a legacy effect on survival following randomization to extended hours dialysis in the ACTIVE Dialysis trial (2020) (5)
Antiplatelet agents for chronic kidney disease (2013) (5)
SP259EFFECTS OF EMPAGLIFLOZIN ON RENAL OUTCOMES ACROSS KDIGO RISK CATEGORIES: RESULTS FROM THE EMPA-REG OUTCOME® TRIAL (2017) (5)
Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial (2021) (5)
Comparison of Circulating Biomarkers in Predicting Diabetic Kidney Disease Progression With Autoantibodies to Erythropoietin Receptor (2020) (5)
New hypoglycemic agents and the kidney: what do the major trials tell us? (2018) (5)
Inequities in the global representation of sites participating in large, multicentre dialysis trials: a systematic review (2019) (5)
Haemolytic uraemic syndrome and prostatic cancer. (1999) (5)
Erratum. The Relative and Combined Ability of High-Sensitivity Cardiac Troponin T and N-Terminal Pro-B-Type Natriuretic Peptide to Predict Cardiovascular Events and Death in Patients With Type 2 Diabetes. Diabetes Care 2014;37:295–303 (2015) (5)
Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction (2018) (5)
Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial (2022) (5)
Management of patients with diabetes and CKD (5)
Glucose lowering therapies for chronic kidney disease and kidney transplantation (2012) (5)
Effect of Hemodiafiltration on the Progression of Neuropathy with Kidney Failure (2021) (4)
Randomised controlled trial of the impact of haemodiafiltration on uraemic neuropathy: FINESSE study protocol (2019) (4)
Comparison of exposure response relationship of atrasentan between North American and Asian populations (2017) (4)
EFFECTS OF CANAGLIFLOZIN ON CARDIOVASCULAR, RENAL AND SAFETY OUTCOMES BY BASELINE LOOP DIURETIC USE: DATA FROM THE CREDENCE TRIAL (2020) (4)
Blood pressure management in diabetes: a path forward? (2011) (4)
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. (2023) (4)
Original Investigation Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials (2015) (4)
Canagliflozin and Renal Outcomes in Diabetic Nephropathy. Reply. (2019) (4)
FP483EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) – A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER (2019) (4)
Individual Atrasentan Exposure is Associated With Long‐term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease (2020) (4)
Dialysis adequacy (HD) guidelines: dose of haemodialysis (2005) (4)
FP482EGFR LOSS WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUE TREATMENT: DATA FROM SUSTAIN 6 AND LEADER (2019) (4)
Is it time for Medi‐change? (2014) (4)
Faculty Opinions recommendation of GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. (2018) (4)
Optimal targets for blood pressure control in chronic kidney disease: the debate continues (2014) (4)
Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program (2021) (4)
The modifiable burden of worldwide mortality from cardiovascular diseases. (2014) (4)
Renoprotection with perindopril-indapamide below current recommended blood pressure targets in patients with type 2 diabetes mellitus: results of the ADVANCE trial (2008) (4)
Quality of Life in Caregivers of Patients Randomized to Standard- Versus Extended-Hours Hemodialysis (2021) (3)
Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta‐analysis (2022) (3)
The relationship between proteinuria and cardiovascular disease: a systematic review (2009) (3)
Variability in estimated glomerular filtration rate and the risk of major clinical outcomes in diabetes: Post hoc analysis from the ADVANCE trial (2021) (3)
ACCORDION: Ensuring That We Hear the Music Clearly. (2018) (3)
Faculty Opinions recommendation of Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. (2018) (3)
How to read a report of a randomized controlled trial (2010) (3)
Side effects and tolerability of combination blood pressure lowering according to blood pressure levels: an analysis of the PROGRESS and ADVANCE trials (2017) (3)
Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS). (2022) (3)
Global kidney disease (2013) (3)
How many Australian deaths from heart disease and stroke could be avoided by a small reduction in population cholesterol levels (2009) (3)
Impact of random variation in albuminuria and estimated glomerular filtration rate on patient enrolment and duration of clinical trials in nephrology (2022) (3)
Knowing what we do not know: statin therapy in advanced chronic kidney disease. (2016) (3)
Blood pressure: at what level is treatment worthwhile? (2019) (3)
Prevention of vascular outcomes in type 2 diabetes: benefits of intensive blood pressure and blood glucose control with Preterax and Diamicron MR, Issue III (2008) (3)
URAEMIC NEUROPATHY REMAINS UBIQUITIOUS: RATIONALE AND FEASIBILITY OF THE FINESSE (FILTRATION IN THE NEUROPATHY OF END STAGE KIDNEY DISEASE SYMPTOM EVOLUTION) TRIAL (2010) (3)
Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysis (2021) (3)
Comparative Efficacy and Safety of BP-Lowering Pharmacotherapy in Patients Undergoing Maintenance Dialysis: A Network Meta-Analysis of Randomized, Controlled Trials. (2020) (3)
Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial (2021) (3)
Effects of Beta-Adrenergic Antagonists in Patients With Chronic Kidney Disease (2011) (3)
Post-Hoc Subgroup Analysis of a Randomized Controlled Trial Aspirin Is Beneficial in Hypertensive Patients With Chronic Kidney Disease: A (2010) (3)
Is it time to REWIND the cardiorenal clock in diabetes? (2019) (2)
Conducting clinical trials in Asia: Why is it important and how can it be done in Asia (2012) (2)
Duration and frequency of haemodialysis therapy (2005) (2)
Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS (2022) (2)
TWENTY YEAR CANCER OUTCOMES OF A RANDOMISED TRIAL OF IMMUNOSUPPRESSION IN KIDNEY TRANSPLANT RECIPIENTS: RESULTS OF THE AUSTRALIAN MULTICENTRE TRIAL OF CYCLOSPORINE WITHDRAWAL: 288 (2008) (2)
EFFECTS OF CANAGLIFLOZIN ON STROKE IN THE CREDENCE TRIAL (2020) (2)
THE FIXED COMBINATION OF PERINDOPRIL AND INDAPAMIDE HAS A GREATER EFFECT ON CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND ALBUMINURIA (2009) (2)
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial (2023) (2)
Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program (2020) (2)
MO051EFFECTS OF SEMAGLUTIDE ON CHRONIC KIDNEY DISEASE OUTCOMES: A POST HOC POOLED ANALYSIS FROM THE SUSTAIN 6 AND PIONEER 6 TRIALS (2020) (2)
Epidemiology: Global Burden of Disease Study 2010: implications for nephrology (2013) (2)
Glomerular filtration rate and the risk of stroke (2010) (2)
SaO010EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAGLUTIDE ON RENAL OUTCOMES – A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS (2019) (2)
Water quality for haemodialysis (2005) (2)
Antihypertensive agents for preventing diabetic kidney disease (Review) (2012) (2)
The predictive ability of different measures of kidney function: new data from the Progress study (2006) (2)
MP221EFFECTS OF ISCHAEMIC CONDITIONING ON MAJOR CLINICAL OUTCOMES IN PEOPLE UNDERGOING INVASIVE PROCEDURES: A SYSTEMATIC REVIEW AND METAANALYSIS (2016) (2)
Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA ® ): A randomized, double-blind, placebo-control (2018) (2)
Rationale, design, demographics and baseline characteristics of the randomized, controlled, Phase 2b SAPPHIRE study of verinurad plus allopurinol in patients with chronic kidney disease and hyperuricaemia (2021) (2)
Effects of fibrates on cardiovascular outcomes – Authors' reply (2010) (2)
Haemodialysis anticoagulation and adequacy (2005) (2)
SO019EFFECTS OF EMPAGLIFLOZIN ON CARDIOVASCULAR OUTCOMES ACROSS KDIGO RISK CATEGORIES: RESULTS FROM THE EMPA-REG OUTCOME® TRIAL (2017) (2)
TO002REDUCTION IN THE RATE OF EGFR DECLINE WITH SEMAGLUTIDE VS PLACEBO: A POST HOC POOLED ANALYSIS OF SUSTAIN 6 AND PIONEER 6 (2020) (2)
The ASCEND-ND trial: study design and participant characteristics (2021) (2)
Investing in healthier lives: Pathways to healthcare financing reform in Australia (2015) (2)
Outcomes associated with extended hours haemodialysis (EHHD) (2010) (2)
Review: Revascularization and medical treatment may be similar in atherosclerotic renal artery stenosis (2016) (2)
Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: insights from the CREDENCE trial (2021) (2)
Higher-Dose Sitagliptin and the Risk of Congestive Heart Failure in Older Adults with CKD. (2020) (1)
The International Society of Nephrology Advancing Clinical Trials (ISN-ACT) Network: current activities and future goals. (2020) (1)
Oral Methylprednisolone and Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy-Reply. (2022) (1)
A Randomized, Placebo-Controlled Trial of Pentoxifylline On Erythropoiesis Stimulating Agent Resistance in Anaemic Patients with Chronic Kidney Disease - the Hero Trial (2014) (1)
Fibrates: Risk Benefits and Role in Treating Dyslipidemias (2015) (1)
129-LB: Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex in the CREDENCE Trial (2021) (1)
Pre-operative Kidney Function as a Predictor of Adverse Outcomes after Surgery: A Systematic Review and Meta-analysis (2011) (1)
New approaches for the prevention of vascular disease in Type 2 diabetes (2008) (1)
P6272First plus recurrent CV and hospitalization events in the CArdiovascular and Renal Microvascular outcomE study with LINAgliptin (CARMELINA) in patients with type 2 diabetes and cardiorenal disease (2019) (1)
Factors associated with survival in elderly dialysis patients (2010) (1)
Interventions for erythropoietin-resistant anaemia in dialysis patients: a systematic review (2010) (1)
EFFECTS OF CANAGLIFLOZIN ON HEART FAILURE OUTCOMES WITH AND WITHOUT PRESERVED EJECTION FRACTION IN TYPE 2 DIABETES: RESULTS FROM THE CANVAS PROGRAM (2019) (1)
Impact of SGLT2 inhibitors on the kidney in people with type 2 diabetes and severely increased albuminuria (2022) (1)
Glucocorticoids for IgA nephropathy-pro. (2023) (1)
WCN23-0412 EFFECT OF IPTACOPAN ON PROTEINURIA AND COMPLEMENT BIOMARKERS OVER TIME IN IgA NEPHROPATHY (2023) (1)
Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria. (2022) (1)
SAT-156 RENAL, CARDIOVASCULAR, AND SAFETY OUTCOMES OF CANAGLIFLOZIN ACCORDING TO BASELINE ALBUMINURIA: A CREDENCE SECONDARY ANALYSIS (2020) (1)
Routine blood pressure lowering and intensive glucose control in patients with Type 2 diabetes: the ADVANCE trial (2009) (1)
432-P: Analyses of First plus Recurrent Cardiovascular and Hospitalization Events in the Cardiovascular and Renal Microvascular Outcome Study with Linagliptin (CARMELINA) in Patients with Type 2 Diabetes and Cardiorenal Disease (2019) (1)
Effects of canagliflozin on cardiovascular death and hospitalization for heart failure by baseline estimated glomerular filtration rate: integrated analyses from the CANVAS Program and CREDENCE (2020) (1)
Aspirin benefit increases as eGFR declines: Results from a randomised controlled trial in a hypertensive population (2010) (1)
First Light After the Long Night: A Follow-up Report of the Randomized FHN Nocturnal Trial. (2015) (1)
MO148A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LNP023 IN PRIMARY IGA NEPHROPATHY PATIENTS (2021) (1)
Haemodialysis duration, frequency and intensity for end-stage kidney disease (2012) (1)
Coronary Heart Disease Isolated Low Levels of High-Density Lipoprotein Cholesterol Are Associated With an Increased Risk of Coronary Heart Disease (2011) (1)
IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study (2023) (1)
Targeting the Alternative Complement Pathway with Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study (2023) (1)
The impact of canagliflozin on the risk of neuropathy events: a post-hoc exploratory analysis of the CREDENCE trial. (2022) (1)
Faculty Opinions recommendation of Efficacy of self-monitored blood pressure, with or without telemonitoring, for titration of antihypertensive medication (TASMINH4): an unmasked randomised controlled trial. (2018) (1)
Faculty Opinions recommendation of Estimating the association of the 2017 and 2014 hypertension guidelines with cardiovascular events and deaths in US adults: an analysis of national data. (2018) (1)
The Safety and Efﬁcacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis (1)
Canagliflozin, serum magnesium and cardiovascular outcomes—Analysis from the CANVAS Program (2021) (1)
Pilot Trials in Nephrology: Establishing a BASE for Large-Scale Randomized Trials. (2020) (1)
EFFECTS OF SGLT2 INHIBITORS ON STROKE IN TYPE 2 DIABETES ACCORDING TO BASELINE KIDNEY FUNCTION (2020) (1)
Update in hypothermia (2013) (0)
Causes of death in patients with chronic kidney disease: insights from the ASCEND-D and ASCEND-ND cardiovascular outcomes trials (2022) (0)
Management of chronic kidney disease in Australian general practice (the AusHEART Study) (2010) (0)
Opportunities in pragmatic trials [invited speaker] (2016) (0)
TREATMENT EFFECT OF CANAGLIFLOZIN FOR PATIENTS ON THERAPY FOR HEART FAILURE: POOLED ANALYSIS OF THE CANVAS PROGRAM AND CREDENCE TRIAL (2023) (0)
Type 2 Diabetes Mellitus Resting Heart Rate and the Risk of Microvascular Complications in Patients With Copyright (2012) (0)
Designing better CV trials in the CKD population (2014) (0)
Authors’ reply to Ladapo and Ogedegbe (2014) (0)
Conventional versus novel ways to manage patients with T2DM – removing excess glucose through SGLT2 inhibition [Invited Presentation] (2013) (0)
High sensitivity cardiac troponin T and N-terminal pro-BNP predict cardiovascular events and death in patients with type 2 diabetes mellitus (2013) (0)
Lower blood pressure and the risk of recurrent stroke in patients with chronic kidney disease: results of the PROGRESS trial (2008) (0)
Faculty Opinions recommendation of Intravenous iron in patients undergoing maintenance hemodialysis. (2019) (0)
27-OR: Effect of Canagliflozin on Total Hospitalization for Heart Failure Events in Patients with Type 2 Diabetes and Chronic Kidney Disease (2020) (0)
The relationship between chronic kidney disease and individual-level socio-economic factors: the three country kidney disease study (3CKD) (2006) (0)
Twenty year cancer outcomes of a randomised trial of immunosuppression in kidney recipients: results of the Australian multi-centre trial of cyclosporine withdrawal (2007) (0)
Author response for "Sodium‐Glucose Co‐transporter‐2 Inhibition and ocular outcomes in patients with Type 2 Diabetes: A Systematic Review and Meta‐Analysis" (2020) (0)
Exenatide in type 2 diabetes (2010) (0)
Designing and running high-quality clinical trials- unlocking better outcomes for patients [invited speaker] (2016) (0)
Cardiovascular complications - 2 (2009) (0)
131-LB: The Impact of Canagliflozin on the Risk of Neuropathy Events: Results from the CREDENCE Trial (2021) (0)
Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial (2022) (0)
Lipid lowering in chronic kidney disease (2009) (0)
Clinical Trials in Diabetic Nephropathy [Invited speaker] (2014) (0)
Moving the field forward: Future randomized trials that will advance CKD and ESRD care (2011) (0)
Interventions for Reduction of Left Ventricular Mass in Chronic Kidney Disease: a Systematic Review and Meta-Analysis of Randomized Controlled Trials (2014) (0)
[Reply] Blood pressure in dialysis patients-look before we leap (2009) (0)
Independent predictors of heart failure in patients with type 2 diabetes and chronic kidney disease: modeling from the CREDENCE trial (2020) (0)
Platform Clinical Trials Within Nephrology-Interpreting the Evidence. (2022) (0)
Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial. (2023) (0)
Proteinuria is associated with a 50% increased risk of coronary heart disease: a meta-analysis of prospective cohort studies (2008) (0)
Presentation improving outcomes for dialysis patients today and tomorrow [invited speaker] (2014) (0)
Effects of linaliptin on glycaemic control and albuminuria in type 2 diabetes - the Marlina-T2D Trial [invited speaker] (2016) (0)
WCN23-0069 EFFICACY AND SAFETY OF REDUCED-DOSE ORAL METHYLPREDNISOLONE IN IGA NEPHROPATHY: THE TESTING TRIAL (2023) (0)
Convection versus diffusion alone in haemodialysis: a systematic review and meta-analysis (2013) (0)
A Novel Risk Prediction Model for Severe Acute Kidney Injury in Intensive Care Unit Patients Receiving Fluid Resuscitation (2022) (0)
Diabetic nephropathy- pushing beyond boundaries [invited speaker] (2015) (0)
MO559ASCEND-ND: STUDY DESIGN AND BASELINE CHARACTERISTICS (2021) (0)
Do men and women respond differently to blood pressure lowering treatment? prospective meta-analysis of randomised trials (2008) (0)
Author response for "Variability in eGFR and the risk of major clinical outcomes in diabetes: post‐hoc analysis from the ADVANCE trial" (2021) (0)
1120-P: Association between the Inflammatory Marker GDF-15 and Kidney Disease Progression: Results from the CANVAS Trial (2020) (0)
Blood pressure in dialysis patients—look before we leap – Authors' reply (2009) (0)
Acute Increase in Creatinine after Starting ACE Inhibitor and Vascular Events and Premature Death in Patients with Type 2 Diabetes—The ADVANCE Trial (2018) (0)
KDIGO Hypertension Guideline Symposium: New data for an old treatment - BP Lowering in 2016 [invited speaker] (2016) (0)
Outcomes of patients receiving extended hours haemodialysis (Ehhd) (2011) (0)
Blood Pressure Lowering Treatment Trialists’ Collaboration — effects of different blood lowering regimens in patients with andwithout diabetes or kidney disease (2003) (0)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. (2017) (0)
POS-019 A NOVEL RISK PREDICTION MODEL FOR SERVE ACUTE KIDNEY INJURY IN INTENSIVE CARE UNIT PATIENTS RECEIVING FLUID RESUSCITATION (2022) (0)
Symposium : Chronic kidney disease and CVD [chair] (2014) (0)
Renal outcome and microalbuminuria data from ADVANCE (2008) (0)
Kidney disease in diabetes [Invited presentation] (2013) (0)
Outcomes in kidney trials (2006) (0)
SAT-041 A META-ANALYSIS OF THE REPRESENTATIVENESS OF RANDOMIZED CONTROLLED TRIAL COHORTS IN END-STAGE KIDNEY DISEASE (2019) (0)
Glucose lowering and the kidney: are all drug classes equal? (2018) (0)
Interventions for lowering plasma homocysteinelevels in kidney transplant recipients [Protocol] (2009) (0)
Author response for "SGLT2 inhibitors with and without metformin: a meta‐analysis of cardiovascular, kidney and mortality outcomes" (2020) (0)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. (2017) (0)
LONG TERM OUTCOMES OF STENT INSERTION FOR RENAL ARTERY STENOSIS (2002) (0)
Exploring future potentials and opportunities with linagliptin and empagliflozin in patients with diabetic kidney disease and associated co-morbidities [chair] (2014) (0)
National Heart Foundation Hypertension Guideline - 2016 (2016) (0)
The efficacy of lower blood pressure goals on the prevention of stroke in chronic kidney disease: data from the PROGRESS study (2007) (0)
pof Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction (2013) (0)
Ultrasound Imaging for R gional Anesthesia in Infants , Children , and Adolescents (2013) (0)
Effects of Fibrates in Chronic Kidney Disease across studies (2012) (0)
Cardiovascular Outcome Trials in chronic kidney disease Patients [session chair] (2015) (0)
Long-term outcomes after acute rejection in kidney transplant recipients (2019) (0)
SAT-298 EFFECT OF SGLT2 INHIBITORS ON CARDIOVASCULAR, RENAL AND SAFETY OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE (2019) (0)
Faculty Opinions recommendation of Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. (2018) (0)
Embedding Big data into health care [session chair] (2016) (0)
SGLT2 and the kidney: What do we know and what are we likely to learn? [invited speaker] (2016) (0)
1098-P: Biomarkers of Tubular Injury and Effects of Canagliflozin in the CANVAS Trial (2020) (0)
The Academic Research Organisation – An evolutionary response to a changing research environment? (2008) (0)
Faculty Opinions recommendation of SGLT2 inhibition for the prevention and treatment of diabetic kidney disease: A review. (2018) (0)
Conducting clinical trials in developing countries (2007) (0)
Abstracts of the 50th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology, 25-27 August, 2014, Melbourne, Australia. (2014) (0)
The Impact of Haemodiafiltration, Haemofiltration and Haemodialysis On Clinical Outcomes: a Systematic Review and Meta-Analysis (2013) (0)
CVD in chronic kidney disease: what do we know? (2014) (0)
Author response for "The Effects of Canagliflozin on Heart Failure and Cardiovascular Death by Baseline Participant Characteristics: Analysis of the CREDENCE Trial" (2021) (0)
Outcomes in home extended hours haemodialysis (HEHHD) (2010) (0)
The renal characteristics of patients with a history of lithium exposure as determined by formal renal function testing (2008) (0)
High quality clinical research: why is it important and how can it be done? [invited speaker] (2014) (0)
Contents Vol. 53, 2022 (2023) (0)
Adiposity and cardiovascular risk: a lifecourse perspective (2014) (0)
SGLT2 inhibitors and outcomes in diabetes and kidney disease-new hope? [invited speaker] (2015) (0)
47 – Meta-Analyses of Blood Pressure Lowering Trials and the Blood Pressure Lowering Treatment Trialists’ Collaboration (2018) (0)
KDIGO Blood Pressure Guideline Presentation (2013) (0)
862-P: Interleukin-6 and Cardiovascular Outcomes in Patients with Type 2 Diabetes: A Post Hoc Analysis of CANVAS Trial (2022) (0)
Proteinuria as a predictor of stroke – a systematic review (2007) (0)
Daprodustat and On-Treatment Cardiovascular Events in Chronic Kidney Disease. Reply. (2022) (0)
Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents - post hoc analyses of the ASCEND-ND and ASCEND-D trials. (2022) (0)
Diabetes Outcome Trials. Transitioning to CV efficacy Trials [invited speaker] (2016) (0)
Blood pressure should be lowered as much as possible in people with type 2 diabetes [debate] (2011) (0)
Renal and microalbuminuria data from ADVANCE (2009) (0)
Management of Diabetes in Diabetic Kidney Disease: Are we doing it right? [session moderator] (2016) (0)
Complications of Diabetes Mellitus: Clinical Studies (2011) (0)
SAT-287 eGFR SLOPE AND THE SUBSEQUENT RISK OF CLINICAL OUTCOMES IN TYPE 2 DIABETES (2019) (0)
Designing the Global Blueprint for Chronic Kidney Disease Care and Research (2016) (0)
Site management issues in international clinical trials (2006) (0)
Faculty Opinions recommendation of Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study. (2019) (0)
Interventions for preventing intradialytic hypotension in haemodialysis patients (2014) (0)
Dialysis membranes (2005) (0)
Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial (2021) (0)
Consideration of ways in the post-marketing setting and, absent conducting RCTs, to obtain data supporting use and dosing recommendations of novel medications in later CKD stages (2016) (0)
Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial (2023) (0)
Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials : A Meta-Analysis of Treatment Effects of Randomized Controlled Trials (2019) (0)
Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure. (2022) (0)
Reductions in the risk of vascular events and stroke in patients with and without chronic kidney disease; new data from the PROGRESS trial (2006) (0)
Opportunities and challenges with large pragmatic trials [invited speaker] (2015) (0)
Original Investigation Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes (2015) (0)
FC 123: Baseline Characteristics of the Flow Trial Population: Kidney Outcomes Trial With Once-Weekly Semaglutide in People With Type 2 Diabetes and Chronic Kidney Disease (2022) (0)
FC 089EFFECTS OF CANAGLIFLOZIN ON MAJOR ADVERSE CARDIOVASCULAR EVENTS BY BASELINE ALBUMINURIA: INTEGRATED ANALYSES FROM THE CANVAS PROGRAM AND CREDENCE TRIAL (2021) (0)
747-P: Baseline Characteristics of Subjects in the Once-Weekly (OW) Semaglutide FLOW Kidney Outcomes Trial (2022) (0)
The Relative and Combined Ability of High Sensitivity Cardiac Troponin T and N-Terminal pro-BNP to Predict Cardiovascular Events and Death in Patients with Type 2 Diabetes Mellitus (2013) (0)
Abstract #289 Effect of Linagliptin on Cardiovascular and Kidney Outcomes in Patients with Type 2 Diabetes and Kidney Disease: Carmelina® (2019) (0)
Design and Population of the VALOR-CKD Study: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating the Efficacy and Safety of Veverimer in Slowing Progression of Chronic Kidney Disease in Patients with Metabolic Acidosis. (2022) (0)
Worldwide access treatment for end-stage kidney disease: a systematic review [invited speaker] (2015) (0)
beta-RECEPTOR ANTAGONISTS IN PATIENTS WITH ADVANCED CHRONIC KIDNEY DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS (2010) (0)
Faculty Opinions recommendation of Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. (2019) (0)
Preventing kidney failure - from diabetes to IgA nephropathy and beyond [invited speaker] (2014) (0)
ematuria in Thin Basement Membrane Nephropathy avid (2005) (0)
Prognostic value of CRP in stable coronary artery disease unclear due to a variety of biases in existing studies, therefore no clinical practice recommendations can be made (2010) (0)
FP484DIFFERENT eGFR THRESHOLDS AND THE RENAL EFFECTS OF CANAGLIFLOZIN: DATA FROM THE CANVAS PROGRAM (2019) (0)
Clinical Trial Design in CKD-MBD (2012) (0)
Canagliflozin and Cardiovascular (CV) Outcomes in Patients with Chronic Kidney Disease (2018) (0)
Reducing cardiovascular risk in people with diabetes and kidney disease (2018) (0)
When should treatment be started for hypertension? (2019) (0)
Anticoagulants for the prevention of intravascular catheter malfunction in haemodialysis: a systematic review and meta-analysis (2012) (0)
How many deaths from heart disease and stroke could be avoided by a small reduction in population cholesterol levels (2008) (0)
New directions in diabetic nephropathy [invited speaker] (2014) (0)
P1019CANAGLIFLOZIN AND RISK OF SKIN AND SOFT TISSUE INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE - A POST-HOC ANALYSIS OF THE CREDENCE TRIAL (2020) (0)
Mortality In Elderly Dialysis Patients: The Association With Demographic, Patient And Practice Variables (2009) (0)
26-OR: Acute Declines in EGFR during Treatment with Canagliflozin and Its Implications for Clinical Practice: Insights from CREDENCE (2020) (0)
Controlling dyslipidemia in chronic kidney disease – are all statins the same? [invited speaker] (2015) (0)
Preventing the cardiovascular complications of kidney failure – have we progressed? [invited speaker] (2015) (0)
Response to: Loutradis, et al. Longer dialysis sessions improve cardiac systolic function by reducing myocardial stunning. (2020) (0)
Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR: A Post Hoc Analysis of the CREDENCE Trial. (2023) (0)
The authors reply:. (2013) (0)
New directions in diabetic nephrology [invited speaker] (2014) (0)
Prevention of CVD, translating evidence into practice [Invited speaker] (2013) (0)
Abstract 6369 - ADVANCE-ON: Long term benefits of intensive glucose control for end-stage kidney disease [abstract] (2014) (0)
20 year outcomes of the Australian multi-centre randomised trial of cyclosporine withdrawal in renal transplantation (2007) (0)
Faculty Opinions recommendation of Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. (2018) (0)
Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure (2022) (0)
Outcomes of Aortic Stenosis—A Comparison of Dialysis Patients Versus Controls (2007) (0)
P1028EFFECTS OF CANAGLIFLOZIN ON MAJOR ADVERSE CARDIOVASCULAR OUTCOMES IN PATIENTS WITH DIFFERENT BASELINE LEVELS OF TYPE 2 DIABETES MELLITUS DISEASE SEVERITY: RESULTS FROM THE CANVAS PROGRAM (2020) (0)
Canagliflozin Reduces All-cause Hospitalization in Patients with Type 2 Diabetes Mellitus (2021) (0)
Oral Anticoagulant Use in Patients With Atrial Fibrillation and Chronic Kidney Disease: A Review of the Evidence With Recommendations for Australian Clinical Practice. (2022) (0)
Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial (2022) (0)
Forever Starts Now: Effects of Glucose-Lowering Therapies on Acute Kidney Injury. (2020) (0)
Faculty Opinions recommendation of Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. (2018) (0)
Tripterigium for the treatment of chronic kidney disease: a systematic review and meta-analysis (2012) (0)
Astra Zeneca Symposium: The Clinical Impact of Hyperkalaemia [invited speaker] (2016) (0)
Reducing the global burden of kidney failure – future directions [invited speaker] (2015) (0)
WCN23-0574 THE ELLEN MEDICAL DEVICES AFFORDABLE POINT-OF-CARE PERITONEAL DIALYSIS SYSTEM - A PILOT STUDY (2023) (0)
ALTITUDE: defining a ceiling for blockade of the renin-angiotensin system? (2016) (0)
Changes in Albuminuria and the Risk ofMajor (2017) (0)
Canagliflozin, mental health adverse events and diabetes: Exploratory analysis of the CREDENCE trial and CANVAS Program (2022) (0)
Blood urea sampling methods (2005) (0)
Clinical trials from bench to beside – PCSK9 case study. (2015) (0)
1216-P: The Effects of Canagliflozin on Uric Acid and Gout in Patients with Type 2 Diabetes in the CANVAS Program (2019) (0)
Chapter 9: Renal and microalbuminuria data from ADVANCE (2009) (0)
1206-P: Effects of Canagliflozin (CANA) on Initiation of Insulin in CANVAS Program (2019) (0)
Faculty Opinions recommendation of The chronic kidney disease Water Intake Trial (WIT): results from the pilot randomised controlled trial. (2018) (0)
Abstract P201: Canagliflozin, Visit-to-visit Blood Pressure Variability, And Risk Of Cardiovascular, Kidney, And Mortality Outcomes: Pooled Individual Participant Data From The CANVAS And CREDENCE Trials (2022) (0)
University of Groningen Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes (2019) (0)
Clinical trials networks and international collaboration [Invited speaker] (2014) (0)
SUN-107 THE PREVALENCE OF CHRONIC KIDNEY DISEASE IN ASIA – A SYSTEMATIC REVIEW AND ANALYSIS (2020) (0)
National health policies and strategies for addressing chronic kidney disease: Data from the International Society of Nephrology Global Kidney Health Atlas (2023) (0)
BP management: evolution or revolution [invited speaker] (2014) (0)
SUN-LB015 Baseline Characteristics and Effects on CV and Kidney Outcomes with Linagliptin Versus Placebo, Across GFR Categories in CARMELINA (2019) (0)
Technical Expertise In Clinical Trials and Translational Research-Australia [invited speaker] (2015) (0)
Statistical Analysis Plan for the Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING) (2021) (0)
Baseline cardiovascular risk in subjects with type 2 diabetes and chronic kidney disease from the FLOW trial (2022) (0)
Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials. (2023) (0)
Research priorities in chronic kidney disease: a priority setting partnership (2014) (0)
SUN-161 CIRCULATING AUTOANTIBODIES TO ERYTHROPOIETIN RECEPTOR AND KIDNEY DISEASE PROGRESSION IN TYPE 2 DIABETES MELLITUS: RESULTS FROM THE ADVANCE STUDIES (2020) (0)
Controversies in CDK, BP targets in CDK- are they necessary? [Plenary / Invited] (2013) (0)
Organic Anion Transporter Gene Variants Associated With Plasma Exposure and Long‐Term Response to Atrasentan in Patients With Diabetic Kidney Disease (2022) (0)
CANAGLIFLOZIN AND RENAL OUTCOMES IN PATIENTS WITH CHRONIC KIDNEY DISEASE (2018) (0)
The importance of urine test (test strip) in CKD management [Invited speaker] (2014) (0)
Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: integrated analysis from the CANVAS Program and CREDENCE trial. (2023) (0)
Critical appraisal of clinical trials (2006) (0)
Factors Associated With Regression Of Left Ventricular Mass Index In The Active Dialysis Trial (2018) (0)
Hypertension management: What are the decision points? [Invited speaker] (2014) (0)
Β-receptor antagonists in advanced chronic kidney disease: a systematic review and meta-analysis (2010) (0)
1130-P: Mediators of the Effects of Canagliflozin (CANA) on Heart Failure (HF) and CV Death in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease (CKD) (2020) (0)
Differing approaches to analyse on-treatment cardiovascular events comparing daprodustat with darbepoetin: results from the ASCEND-ND trial (2022) (0)
Cost effectiveness of screening for the early diagnosis and treatment of factors for chronic kidney disease: a Markov Monte-Carlo microsimulation using MARCK-E (Model for the Assessment of Risk factors for Chronic Kidney disease – Economics) (2006) (0)
Approach to partnership - academia, pharma, and governmental organization in developed and developing countries, message from Australia [invited speaker] (2014) (0)
Outcomes in renal trials (2005) (0)
388-P: Interrelationship between Hypoglycemia and CV and Mortality Outcomes in Type 2 Diabetes in the CARMELINA Trial (2019) (0)
139-LB: The Redox Balance Predicts Both Cardiovascular (CV) and Renal Outcomes in CANVAS (2020) (0)
Faculty of 1000 evaluation for Balanced Crystalloids versus Saline in Noncritically Ill Adults. (2018) (0)
Faculty Opinions recommendation of Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. (2018) (0)
Primary and secondary prevention of Diabetes and its complications (2011) (0)
Abstract 18957: Rationale, Design, and Analysis of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R) - A Randomized, Placebo-Controlled Trial (2016) (0)
P1013CANAGLIFLOZIN AND RISK OF GENITAL INFECTIONS AND URINARY TRACT INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE- A POST-HOC ANALYSIS OF THE CREDENCE TRIAL (2020) (0)
Letter by Matthews et al Regarding Article, "Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist". (2018) (0)
Abstract 14752: Canagliflozin Reduces Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Chronic Kidney Disease Regardless of Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial (2019) (0)
SHARP study planning meeting and Arterial Stiffness substudy (2003) (0)
Challenges and operation of a large phase 3 program (2015) (0)
Protection against cardiovascular and renal disease in type 2 diabetes: ADVANCEs in the control of blood pressure using Preterax and Diamicron MR. (2010) (0)
InterAsia: prevalence of renal impairment in Thailand (2003) (0)
Mission Critical: Pressures, Priorities and Australia’s Healthcare Agenda [invited speaker] (2016) (0)
Routine blood pressure lowering and kidney disease in type 2 diabetes (2009) (0)
Type 2 Diabetes: Novel approaches to a complex condition – introducing the SGLT2 inhibitors [invited speaker] (2014) (0)

This paper list is powered by the following services:

Other Resources About Vlado Perkovic

en.wikipedia.org

What Schools Are Affiliated With Vlado Perkovic?

Vlado Perkovic is affiliated with the following schools: